2016, Número 619
<< Anterior Siguiente >>
Rev Med Cos Cen 2016; 73 (619)
Síndrome de Sjögren primario
Pizarro MD
Idioma: Español
Referencias bibliográficas: 18
Paginas: 395-401
Archivo PDF: 176.66 Kb.
RESUMEN
Es probable que en el futuro,
el estudio de varios factores
de riesgo genéticos constituya
una herramienta diagnóstica,
o bien predictiva, que permita
una clasificación más certera
de los pacientes con SSp.
Lamentablemente, no hay
suficiente evidencia científica que
valide los tratamientos utilizados
hasta la fecha, y que puedan ser
utilizados en una gran parte de la
población afectada, debido a las
diferencias en manifestaciones
clínicas del síndrome. Es de
importancia estudiar y recordar
las manifestaciones clínicas del
SSp, así como las herramientas
disponibles para su diagnóstico;
ya que es una enfermedad de
gran importancia clínica y que
está subdiagnosticada en nuestra
población adulta mayor.
REFERENCIAS (EN ESTE ARTÍCULO)
Abdulahad W., Kroese F., Vissink A., Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjögren’s syndrome, Journal of Autoimmunity. 2012; 39 (1–2): 103-111.
Alunno A., Carubbi F., Bartoloni F., Bistoni O., Caterbi S., Cipriani P., et al. Unmasking the pathogenic role of IL-17 axis in primary Sjögren’s syndrome: A new era for therapeutic targeting? Autoimmunity Reviews, 2014; 13 (12): 1167-1173.
Baldini C., Talarico R., Tzioufas A., Bombardieri S. Classification criteria for Sjogren’s syndrome: A critical review, Journal of Autoimmunity, 2012; 39 (1–2): 9-14.
Barrera M., Bahamondes V., Sepúlveda D., Quest A., Castro I., Cortés J., et al. Sjögren’s syndrome and the epithelial target: A comprehensive review, Journal of Autoimmunity. 2013; 42: 7-18.
Burbelo P., Ambatipudi K., Alevizos I. Genome-wide association studies in Sjögren’s syndrome: What do the genes tell us about disease pathogenesis? Autoimmunity Reviews. 2014; 13 (7): 756-761.
Castro I., Sepúlveda D., Cortés J., Quest A., Barrera M., Bahamondes V., et al. Oral dryness in Sjögren’s syndrome patients. Not just a question of water, Autoimmunity Reviews, 2013; 12 (5): 567-574.
Colafrancesco S., Perricone C., Priori R., Valesini G., Shoenfeld Y. Sjögren’s syndrome: Another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA), Journal of Autoimmunity. 2014; 51: 10-16.
Cornec D., Jamin C., Pers J. Sjögren’s syndrome: Where do we stand, and where shall we go?, Journal of Autoimmunity, 2014; 51: 109-114.
Guellec D., Cornec D., Jousse- Joulin S., Marhadour T., Marcorelles P., Pers J., et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren’s syndrome: A systematic review, Autoimmunity Reviews, 2013; 12 (3): 416-420.
Hernández G., Leal G., Michel M. The meaning of anti-Ro and anti La antibodies in primary Sjögren’s syndrome, Autoimmunity Reviews. 2011; 10, (3): 123-125.
Ice J., Li H., Adrianto I., Chee Lin P., Kelly J., Montgomery C., et al. Genetics of Sjögren’s syndrome in the genome-wide association era, Journal of Autoimmunity. 2012; 39 (1–2): 57-63.
Kivity S., Arango M., Ehrenfeld M., Tehori O., Shoenfeld Y., Anaya J., et al. Infection and autoimmunity in Sjogren’s syndrome: A clinical study and comprehensive review, Journal of Autoimmunity. 2014; 51: 17-22.
Kramer J. Early events in Sjögren’s Syndrome pathogenesis: The importance of innate immunity in disease initiation. Cytokine 2014; 67 (2): 92-101.
Kyriakidis N., Kapsogeorgou E., Tzioufas A. A comprehensive review of autoantibodies in primary Sjögren’s syndrome: Clinical phenotypes and regulatory mechanisms, Journal of Autoimmunity. 2014; 51: 67-74.
Pavlakis P., Alexopoulos H., Kosmidis M., Mamali I., Moutsopoulos H., Tzioufas A., et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms, Journal of Autoimmunity. 2012; 39 (1–2): 27-33.
Seror R., Theander E., Bootsma H., Bowman S., Tzioufas A., Gottenberg J., et al. Outcome measures for primary Sjögren’s syndrome: A comprehensive review, Journal of Autoimmunity. 2014; 51: 51-56.
Tobón G., Pers J., Youinou P., Saraux S. B cell-targeted therapies in Sjögren’s syndrome, Autoimmunity Reviews, 2010; 9 (4): 224-228.
Yao Y., Liu Z., Jallal B., Shen N., Rönnblom L. Type I interferons in Sjögren’s syndrome, Autoimmunity Reviews. 2013; 12 (5): 558-566.